Cereno Scientific AB Series B

CRNO-B · Nasdaq Stockholm · Healthcare

4.05SEK −0.8%last day

Price as of 2 October 2026

The price over the past year, with dividends: −54.4%

Performance

1 month

−4.5%

1 year

−54.4%

3 years, per year

+13.9%

5 years, per year

−0.7%

Largest fall, 3 years

−66.0%

Below the peak now

−65.5%

Volatility, 1 year

57.5%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

6.1

Dividend yield

0.0%

Return on equity

−63.1%

Net margin

–

Market value

126 m USD

Quality, value and trend

Where Cereno Scientific stands against every Nordic stock today. 100 is best.

Quality33

Profitability and a sound balance sheet over time. Better than 33% of Nordic stocks.

Value3

The price measured against earnings, assets and cash flow. Better than 3% of Nordic stocks.

Trend6

The price development over the past year. Better than 6% of Nordic stocks.

Combined2

Quality, value and trend together. Better than 2% of Nordic stocks.

About Cereno Scientific

Cereno Scientific AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis